The useful question is not whether a longevity platform sounds futuristic. It is whether its claims can be tested against prediction, intervention response, replication, and clinical outcomes.
Recent longevity deals are not funding one grand anti-aging thesis. They are clustering around businesses that make longevity legible as diagnostics, animal-health therapeutics, and platform discovery.
Longevity brands do not get into trouble because they mention healthspan. They get into trouble when prevention language quietly becomes diagnosis, treatment, cure, mitigation, or disease-risk reduction.
Abu Dhabi’s healthy longevity medicine framework is not just another wellness initiative. It is an early test of what regulated longevity care might look like when clinics, data infrastructure, and licensing standards meet.
The biomarker field in longevity now has a familiar problem: it is producing more interesting measurements than medicine yet knows
The DO-HEALTH omega-3 paper became one of those longevity studies that was easy to summarize too quickly. A daily gram
Few ideas in longevity science remain as intuitively powerful as senolytics. If aging tissues accumulate senescent cells — damaged cells
For years, chronic inflammation sat in longevity science as both a familiar fact and a slightly unsatisfying explanation. Everyone knew
Longevity companies often talk as if their advantage lies in a proprietary clock, a sharper scan, a larger omics panel,
There is a temptation to talk about longevity investing as if it were a single sector. It is not. The